INDOCO vs PGHL: Stock Comparison

Indoco Remedies Limited vs Procter & Gamble Health Limited

Live data: 22 July 2026, 2:52 PM IST • Source: NSE and company filings

Procter & Gamble Health Limited is the larger company by market capitalisation. Indoco Remedies Limited shows a lower P/E and faster revenue growth, while Procter & Gamble Health Limited shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Indoco Remedies Limited and Procter & Gamble Health Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, INDOCO is more favourable on 4 of 13 scored metrics and PGHL on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
PGHL is the larger company
₹11,172 Cr vs ₹2,160 Cr
P/E Ratio
INDOCO has a lower P/E
-23.83x vs 34.28x
P/B Ratio
INDOCO has a lower P/B
2.41x vs 21.36x
EPS
PGHL has higher earnings per share
₹196.64 vs ₹-10.71
Dividend Yield
PGHL has a higher dividend yield
2.34% vs 0.08%
Revenue Growth (TTM YoY)
INDOCO has faster revenue growth
21.9% vs 19.1%
EPS Growth (TTM YoY)
PGHL has faster EPS growth
54.6% vs 0%
Qtr Sales Growth
INDOCO has stronger quarterly sales growth
21.9% vs 19.1%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricINDOCOPGHL
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricINDOCOPGHL
Live Price₹233.99₹6,737
Day Change-4.82%-0.63%
Volume71,6884,521
52-Week High₹336₹6,975
52-Week Low₹162.19₹4,707
Distance from 52W High-30.36%-3.41%

Valuation

MetricINDOCOPGHL
Market Cap₹2,160 Cr₹11,172 Cr
P/E Ratio-23.83x34.28x
P/B Ratio2.41x21.36x
EPS₹-10.71₹196.64
Book Value₹111.55₹316.01
Dividend Yield0.08%2.34%

Growth

MetricINDOCOPGHL
Revenue Growth (TTM YoY)21.9%19.1%
EPS Growth (TTM YoY)0%54.6%
Qtr Sales Growth21.9%19.1%
Qtr Profit Growth39%54.6%

Profitability & Leverage

MetricINDOCOPGHL
ROE-9.42%61.6%
ROCE0.93%83.5%
Net Margin-5.31%23.22%
Operating Margin7.68%32.4%
Debt to Equity1.16x0.02x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricINDOCOPGHL
Promoter Holding58.86%0%
FII Holding1.27% 0.33 pp6.33% 0.13 pp
DII Holding17.68% 0.47 pp12.44% 1.23 pp
Public Holding22.04% 0.14 pp29.42% 1.11 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Indoco Remedies Limited and Procter & Gamble Health Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.